Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletion.
Venn NC, van der Velden VH, de Bie M, Waanders E, Giles JE, Law T, Kuiper RP, de Haas V, Mullighan CG, Haber M, Marshall GM, Md N, van Dongen JJ, Sutton R. Venn NC, et al. Among authors: de bie m, de haas v. Leukemia. 2012 Jun;26(6):1414-6. doi: 10.1038/leu.2011.348. Epub 2011 Dec 9. Leukemia. 2012. PMID: 22157735 Free PMC article. No abstract available.
The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia.
de Haas V, Breunis WB, Dee R, Verhagen OJ, Kroes W, van Wering ER, van Dongen JJ, van den Berg H, van der Schoot CE. de Haas V, et al. Br J Haematol. 2002 Jan;116(1):87-93. doi: 10.1046/j.1365-2141.2002.03228.x. Br J Haematol. 2002. PMID: 11841400 Free article.
Is there a relationship between in vitro drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia?
De Haas V, Kaspers GJ, Oosten L, Bresters D, Pieters R, Van Der Velden VH, Van Wering ER, Van Den Berg H, Van Der Schoot CE. De Haas V, et al. Br J Haematol. 2002 Sep;118(4):1190-1. doi: 10.1046/j.1365-2141.2002.36211.x. Br J Haematol. 2002. PMID: 12199807 Free article. No abstract available.
Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V, Veerman AJ, van Kessel AG, Hoogerbrugge PM, Kuiper RP, van Dongen JJ. Waanders E, et al. Among authors: de haas v. Leukemia. 2011 Feb;25(2):254-8. doi: 10.1038/leu.2010.275. Epub 2010 Nov 19. Leukemia. 2011. PMID: 21102428
Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS.
Westers TM, van der Velden VH, Alhan C, Bekkema R, Bijkerk A, Brooimans RA, Cali C, Dräger AM, de Haas V, Homburg C, de Jong A, Kuiper-Kramer PE, Leenders M, Lommerse I, te Marvelde JG, van der Molen-Sinke JK, Moshaver B, Mulder AB, Preijers FW, Schindhelm RK, van der Sluijs A, van Wering ER, Westra AH, van de Loosdrecht AA; Working Party on Flow Cytometry in MDS of Dutch Society of Cytometry (NVC). Westers TM, et al. Among authors: de jong a, de haas v. Leuk Res. 2012 Apr;36(4):422-30. doi: 10.1016/j.leukres.2011.09.015. Epub 2011 Oct 6. Leuk Res. 2012. PMID: 21982641
Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.
Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JP, Beverloo HB, Zimmermann M, de Haas V, Richards SM, Vora AJ, Mitchell CD, Russell LJ, Schwab C, Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, den Boer ML, Zwaan CM. Buitenkamp TD, et al. Among authors: de haas v. Leukemia. 2012 Oct;26(10):2204-11. doi: 10.1038/leu.2012.84. Epub 2012 Mar 22. Leukemia. 2012. PMID: 22441210
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R. Marshall GM, et al. Among authors: de haas v, de bont es, de groot kruseman ha. Leukemia. 2013 Jul;27(7):1497-503. doi: 10.1038/leu.2013.44. Epub 2013 Feb 14. Leukemia. 2013. PMID: 23407458 Clinical Trial.
132 results